BJ
EPZM

BlackRock Japan’s Epizyme, Inc EPZM Stock Holding History

BlackRock Japan’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-446
Closed -$8K – 1405
2014
Q4 		$8K Buy
+446
New +$10.4K ﹤0.01% 1282
2013
Q4 		– Sell
-5,477
Closed -$219K – 1435
2013
Q3 		$219K Buy
+5,477
New +$185K ﹤0.01% 881

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

BlackRock Japan's EPZM Position: Q1 2015 in Review

BlackRock Japan sold out of Epizyme, Inc (EPZM) in Q1 2015, closing a stake of 446 shares — an estimated $8K sold.

BlackRock Japan first reported a position in EPZM in Q3 2013 and held it in 2 quarters. The position peaked at $219K in Q3 2013. 103 funds tracked by Wall St. Rank hold EPZM as of Q1 2015.

  • BlackRock Japan reported no remaining Epizyme, Inc position as of Q1 2015 after selling out during the quarter.
  • BlackRock Japan sold 446 Epizyme, Inc shares in Q1 2015, an estimated $8K.
  • BlackRock Japan first reported a position in Epizyme, Inc in Q3 2013 and held it in 2 quarters.
  • BlackRock Japan's Epizyme, Inc position peaked at $219K in Q3 2013.
  • 103 funds tracked by Wall St. Rank held Epizyme, Inc as of Q1 2015.

Based on BlackRock Japan's 13F filing for Q1 2015, filed 13 May 2015.